Clinical Benefit of Using a Multifractional Er:YAG Laser Combined With a Spatially Modulated Ablative (SMA) Module for the Treatment of Striae Distensae: A Prospective Pilot Study in 20 Patients

Jean Paul Meningaud, MD, PhD, Mounia SidAhmed-Mezi, PhD, Raphaëlle Billon, MD, Kessara Rem, MD, Simone La Padula, MD, and Barbara Hersant, MD, PhD

Department of Plastic, Reconstructive and Maxillo facial Surgery, Hopital Henri Mondor, Creteil 94010, France

Background and Objective: Striae distensae (SD) are cutaneous lesions that often occur on the breasts, abdomen, hips, and thighs. The aim of this study is to evaluate the effectiveness of a new technique using a non-invasive Er:YAG laser combined with Spatially Modulated Ablation (SMA) module for the treatment of SD.

Study Design/Materials and Methods: This prospective pilot clinical study included 20 patients with skin phototypes I to IV who are affected by SD. The Er:YAG 2940 nm laser with SMA module was used in scanning mode with fluences of 2.3 J/cm², frequency of 3 Hz, and pulse duration of 0.3 milliseconds. The laser beam is split into several microspots and penetrates only by 50 μm in the epidermis thickness. This technology induces also the generation of acoustic waves to stimulate tissue regeneration. Each patient underwent six laser sessions. An objective and subjective assessment of SD were used. All adverse events were reported.

Results: Most patients reported good improvement and expressed their satisfaction with the treatment. Cutometric analysis showed significant improvement in skin elasticity at the end of study. Moreover, ultrasound analysis revealed an increase in dermal thickness (P < 0.01). POSAS scores decreased significantly at 3 and 6 months, reflecting improved skin quality. The average recovery time was 5 days, with no adverse effects reported.

Conclusion: Using Er:YAG laser (2,940 nm) with SMA technology to treat SD resulted in improved volume and textural appearance with minimal time recovery. Lasers Surg. Med. © 2018 Wiley Periodicals, Inc.

Key words: laser; microablative; Er:YAG; spatially modulated ablative module; striae distensae; stretch marks; RecoSMA; SMA

INTRODUCTION

Striae distensae (SD), or stretch marks, are dermal scars. Initially SD appears erythematous and purplish in color (striae rubrae), over time they atrophy and lose their pigmentation to become pearlenscent white (striae albae) [1]. This common dermatologic condition causes distress for aesthetic reasons, potentially creating a psychological burden for patients. Stretch marks frequently occur during pregnancy, obesity, rapid weight loss, Cushing’s syndrome, or following treatment with topical or systemic corticosteroids [2–4].

From a histological viewpoint, SD are scars with bundles of stretched, atrophied collagen resulting in a loss of around 50% of dermal thickness and elastic fibers [5,6].

It is difficult to remove stretch marks, and to date, few treatment methods have proven to be effective. Various therapeutic approaches are available to treat stretch marks but they have met with limited success in terms of efficacy: tretinoin-based creams are often used to prevent these dermal lesions [7,8] as are hydrating creams [9,10], chemical peels [11,12], microdermabrasion [13,14], radiofrequency devices [15], intense pulsed light [16,17], and needling therapy [18,19].

A number of studies have shown the effect of lasers at different wavelengths to stimulate fibroblasts [20]. Non-ablative laser techniques were used to treat SD including, pulsed-dye laser (PDL) [21], excimer laser [22], the 1064 nm neodymium-doped YAG (Nd-YAG) [23], and the 577 nm copper bromide laser [24]. Improvement in SD after fractional nonablative laser were also reported [25–28]. Ablative lasers were also used to improve the SD, they include the CO₂ laser [29] but this technique presents a risk of hyperpigmentation for dark phototypes [30].
A non-ablative fractional laser uses reconstructive Spatially Modulated Ablation (RecoSMA) technology was used in our study. This new, non-invasive technology can be equipped with an erbium-doped yttrium aluminum garnet (Er:YAG) laser operating at a wavelength of 2,940 nm (which allows the absorption of water molecules) and fitted with a specially designed Spatially Modulated Ablation (SMA) nozzle. The laser beam is fractionated into thousands microbeams (around 10,000 per square cm). Each microbeam measures 50 µm in diameter, and they are spaced 50 µm apart. Thus, the advantage of this technology is that the laser induces minimal ablative and thermal effects, since the beam penetrates only 50 µm into the thickness of the epidermis.

Moreover, this technology induces the generation of acoustic waves at depths of 3–6 mm, allowing superficial destruction of the epidermis, leading to tissue regeneration. The superficial absorption of the laser energy by the tissue, as well as the transmission of powerful acoustic waves, cause micro-traumas resulting in very superficial microablation of the epidermis. This is sufficient to remove several layers of epidermal cells without exceeding the thickness of this cutaneous layer, and without generating fibrous tissue, due to the absence of thermal damage [31–33]. Unlike conventional lasers, the RecoSMA technology is a non-fractional, non-thermal method (skin temperature remains stable at 36.6 °C and thermal effect is minimal). This method is micro-ablative. The epidermis undergoes minimal damage (50 µm microbeams) and the skin’s protective function as a barrier is not compromised, which limits side effects and reduces recovery time, unlike ablative lasers that create a high risk of hyperpigmentation, particularly among dark-skinned patients [34,35]. The histological results using this technology highlighted changes in the thickness of the epidermis, with an increase in newly formed collagen fibers observed below the epidermal-dermal junction. Neovascularization was also observed [31].

The aim of this treatment is to stimulate the fibroblasts and improve or restore skin quality in the areas affected by stretch marks. The body’s reaction to these microperforations is cellular stimulation and regeneration, which results in the restructuring of newly formed collagen and elastin fibers. Our aim with this prospective pilot study was to provide an objective and a subjective assessment of the efficacy and tolerance of the 2,940-nm Er:YAG RecoSMA laser for the treatment of stretch marks among a patient population representing a range of Fitzpatrick skin phototypes.

MATERIALS AND METHODS

Study Design and Patients

This monocentric prospective clinical study was conducted in the Plastic Surgery Department of Henri Mondor Hospital (Créteil, France). Between April 2015 and March 2016, we enrolled and treated a total of 20 patients presenting stretch mark scars of various stages of maturity, based on the Deprez–Adatto classification of stretch marks: stages I, IIa, IIb, IIIa or IIIb, and IV [36]. Based on a 20% effect size for the Er:YAG laser + SMA (RecoSMA), a 5% bilateral alpha risk, and an 80% beta risk, it was determined that 18 patients were necessary for this study. Based on a 10% loss to follow-up or non-evaluable data, we included 20 patients in the study. Pregnant and breastfeeding women and women who had undergone treatment for stretch marks in the previous 6 months were excluded from the study. We also excluded patients with scarring disorders (hypertrophic scarring and keloids), a history of skin cancer, patients with a heart pacemaker or metallic implant, as well as patients with an inflammatory disease and those with vitiligo. All patients signed a written informed consent form.

Treatment With Er:YAG Laser Combined With RecoSMA Technology

Prior to treatment, the area to be treated was disinfected with chlorhexidine solution. No anesthesia was used.

Patients received treatment with the Multiline™ Er:YAG laser (device manufactured by LINLINE Medical System, Minsk, Belarus) combined with RecoSMA technology.

The device was attached to a hand-piece in the beam output window. The RecoSMA module ensured the necessary spatial distribution of laser beam energy. Treatment was performed in scanning mode with the following dose: 2.3 J/cm² (deep RecoSMA) with a frequency of 3 Hz and pulse duration of 0.3 microseconds. One site per patient was treated (either abdomen or buttock or thigh or lower back). When SD is bilateral, both sides were treated. Each patient received six laser sessions, which took place at 1-month intervals.

Objective Assessment

All measurements were made in the same area of SD. Before the first treatment session, we tattoo the area of SD where the measurements will be made. For others treatment sessions and the follow-up, we checked the picture took the first time to perform the measurements (ultrasound and elasticity) and take the pictures at the same area where SD are located. For skin elasticity and ultrasound measurements we take the mean of two measurements when SD is bilateral.

Measuring skin elasticity. The mechanical properties of the skin were determined using a non-invasive suction device to measure skin elasticity (Cutometer® MAP580, Courage and Khazaka Electronic GmbH, Cologne, Germany). We used a 2 mm diameter measuring probe and applied constant suction at 450 mbar for 1 second, following by 1 second of relaxation, repeated three times. We took measurements at the start of treatment, as well as 3 and 6 months after the final laser treatment session.

Using the cutometer software, we calculated the mechanical parameters: R2, R5, R6, and R7. R2 refers to gross elasticity. R5 refers to the net elasticity in the absence of viscous deformation, calculated by the
“immediate retraction”/“immediate distention” ratio R5 = Ur/Ue, where a value close to one (100%) indicates very elastic skin. R6 represents the portion of viscoelasticity on the elastic part of the curve, represented by the “viscoelastic”/“elastic distention” ratio: R6 = Uv/Ue. Since the parameter R6 measures the skin’s stretching capacity, negative values reflect improved skin condition. R7 refers to recovery after deformation; this is the portion of elasticity compared to the final distention. It is calculated using the “immediate retraction”/“final distention” ratio: R7 = Ur/Uf, where a value close to one (100%) indicates very elastic skin.

Ultrasound assessment. Assessment based on ultrasound images was carried out using the Dub1 cutis skin scanner system (Taberna pro medicum, Lüneburg, Germany), a high-resolution ultrasound system with a 22 MHz transducer able to monitor depths of up to 6–7 mm, including the epidermis, the dermis and part of the subcutaneous adipose tissue. We performed ultrasound assessment before starting treatment and 6 months after the last laser session.

Subjective Assessment

Photographs. Photographs were taken using a Canon DS126231 camera with a macrophoto lens before starting treatment and after each treatment session, as well as at 6 months (end of study).

Patient and observer scar assessment scale (POSAS). The Patient and Observer Scar Assessment Scale (POSAS) was used to evaluate the skin quality of stretch marks prior to treatment and at the end of the study. The POSAS score is the combined total of all scores obtained using two scales: the Patient Scar Assessment Scale (PSAS) and the Observer Scar Assessment Scale (OSAS). The POSAS scale was performed by blinded physician assessor in the presence of patient [37].

Patient satisfaction scale. Improvement in the appearance of stretch marks was measured using a 5-item Likert scale: no improvement, slight improvement, moderate improvement, good improvement, and very good improvement of the stretch mark scar [38].

Evaluating Tolerance

Any pain during treatment was assessed using the Visual Analog Scale (VAS from 1 to 10). Side effects and potential complications were recorded at each visit.

Follow-Up Visits

Two follow-up visits were scheduled with patients: one at 3 months and another 6 months after the final treatment session.

Statistical Analysis

We used PRISM, version 5 (GraphPad Software, La Jolla, CA) to analyze the elasticity values of the different parameters and the thickness of the dermis based on ultrasound assessment. Fluctuations in the percentage of the different parameters were determined using the following equation: percentage of change = [(a – b)/b] × 100, where “a” was the individual value of R5, R6, or R7 at 6 months and “b” was the corresponding zero-time (before treatment). The Student’s t-test was used to compare the mean values. P < 0.05 was considered to be statistically significant. The Tukey test was used for many different comparisons.

RESULTS

Clinical and Demographic Characteristics of Patients Enrolled in the Study

Table 1 presents demographic information about study participants. We enrolled 20 patients to take part in this study. Study participants were aged from 21 to 58 years, with a mean age of 35.7 ± 11.47. The mean BMI was 23.73 ± 3.49. The patient population was 85% white (Caucasian), 10% North African, and 5% African. The Fitzpatrick skin phototypes of participants included: phototype I, 30%; phototype II, 25%; phototype IV, 25%; phototype III, 10%; and phototype VI, 10% (Table 1).

Study participants underwent treatment for stretch marks at various stages of maturity and located at different sites on the body. Of the SD that were treated, 50% were on the abdomen; 30% on the buttocks; 10% on the lower back; and 5% on the thighs (Table 1). Each patient was treated on a single area of the SD example: abdomen or buttock or thigh or lower back. In the case where the stretch mark is bilateral, both sides were treated.

According to the Deprez–Adatto classification of stretch marks, 40% of the patients’ stretch marks corresponded to stage IIb (white, superficial striae without rung but with palpable depression at the surface of the skin); 20% to stage IIIa (white, atrophic striae with rung measuring less than

<table>
<thead>
<tr>
<th>TABLE 1. Demographic and Clinical Data of Patients Included in the Study</th>
<th>Number (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phototype</td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>6 (30)</td>
</tr>
<tr>
<td>II</td>
<td>5 (25)</td>
</tr>
<tr>
<td>III</td>
<td>2 (10)</td>
</tr>
<tr>
<td>IV</td>
<td>5 (25)</td>
</tr>
<tr>
<td>VI</td>
<td>2 (10)</td>
</tr>
<tr>
<td>Distribution of SD</td>
<td></td>
</tr>
<tr>
<td>Abdomen</td>
<td>10 (50)</td>
</tr>
<tr>
<td>Buttocks</td>
<td>7 (30)</td>
</tr>
<tr>
<td>Lower back</td>
<td>2 (10)</td>
</tr>
<tr>
<td>Thigh</td>
<td>1 (5)</td>
</tr>
<tr>
<td>Type of SD</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>1 (5)</td>
</tr>
<tr>
<td>2a</td>
<td>2 (10)</td>
</tr>
<tr>
<td>2b</td>
<td>8 (40)</td>
</tr>
<tr>
<td>3a</td>
<td>4 (20)</td>
</tr>
<tr>
<td>3b</td>
<td>4 (20)</td>
</tr>
<tr>
<td>4</td>
<td>1 (5)</td>
</tr>
<tr>
<td>SD, striae distensae.</td>
<td></td>
</tr>
</tbody>
</table>
TABLE 2. Tukey’s Multiple Comparison Test: Parameters of Elasticity Before Treatment and at 3 and 6 Months After Treatment

<table>
<thead>
<tr>
<th>Tukey’s multiple comparisons test</th>
<th>Mean Diff.</th>
<th>95.00% CI of diff.</th>
<th>Summary</th>
<th>Adjusted P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>R2:Before treatment vs. R2:3 months</td>
<td>-0.1439</td>
<td>-0.24 to -0.04784</td>
<td>****</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>R2:Before treatment vs. R2:6 months</td>
<td>-0.1443</td>
<td>-0.2404 to -0.04819</td>
<td>****</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>R5:Before treatment vs. R5:3 months</td>
<td>-0.1485</td>
<td>-0.2446 to -0.0524</td>
<td>****</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>R5:Before treatment vs. R5:6 months</td>
<td>-0.2452</td>
<td>-0.3413 to -0.1491</td>
<td>****</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>R5:3 months vs. R5:6 months</td>
<td>-0.09672</td>
<td>-0.1928 to -0.0006336</td>
<td>*</td>
<td>0.0469</td>
</tr>
<tr>
<td>R6:Before treatment vs. R6:3 months</td>
<td>0.1142</td>
<td>0.01816 to 0.2103</td>
<td>**</td>
<td>0.0063</td>
</tr>
<tr>
<td>R6:Before treatment vs. R6:6 months</td>
<td>0.1172</td>
<td>0.02112 to 0.2133</td>
<td>**</td>
<td>0.0043</td>
</tr>
<tr>
<td>R6:3 months vs. R6:6 months</td>
<td>0.002967</td>
<td>-0.09312 to 0.09905</td>
<td>ns</td>
<td>&gt;0.9999</td>
</tr>
<tr>
<td>R7:Before treatment vs. R7:3 months</td>
<td>-0.1109</td>
<td>-0.2069 to -0.01476</td>
<td>**</td>
<td>0.0096</td>
</tr>
<tr>
<td>R7:Before treatment vs. R7:6 months</td>
<td>-0.1007</td>
<td>-0.1968 to -0.004614</td>
<td>*</td>
<td>0.0308</td>
</tr>
<tr>
<td>R7:3 months vs. R7:6 months</td>
<td>0.01015</td>
<td>-0.08594 to 0.1062</td>
<td>ns</td>
<td>&gt;0.9999</td>
</tr>
</tbody>
</table>
before treatment and 13.0 ± 4.3 months after treatment, 
\(P < 0.0001\) and 6 months (26.1 ± 9.0 before treatment and 
12.85 ± 2.34 at 6 months after treatment, \(P < 0.0001\)).
Moreover, the results of the mean of observer POSAS score
(OSAS) also indicated significant improvement in skin
quality at 3 months: from 28.5 ± 9.5 before treatment to
12.2 ± 4.9 3 months after treatment (\(P < 0.0001\)). At
6 months, the score had also improved significantly
(from 28.5 ± 9.5 before treatment to 12.85 ± 3.71 at
6 months (\(P < 0.0001\)) (Figs. 5 and 6).

**Analysis of patient satisfaction.** In terms of patient
satisfaction, 70% of study participants reported good
improvement of SD scars, expressing satisfaction; 15%
very good improvement; 10% moderate improvement; and
only 5% slight improvement. No patients reported zero
improvement (Fig. 7). The patients who had moderate
and slight improvement had phototype I, the SD were located
in the abdomen and the causes of the apparition of SD is
the pregnancy. For the one who had noticed slight
improvement, the maturity of SD was of 21 years and
the stage of SD according to the Deprez–Adatto classifica-
tion was IV. For the two patients who noticed moderate
improvement, the stage of SD was IIIb and the maturity of
the SD was of 32 years for one and for the other one it was
20 years.

No complications or undesirable side effects were
reported during this study. In the period immediately
following a session, edema, and hyperemia occurred 5–10
minutes after treatment. The average recovery period after
a treatment session was 4 days. Patients described pain
during treatment as tolerable, with an average of
3.95 ± 0.32 on the visual analog scale (VAS).

**DISCUSSION**

A large portion of the global population is affected by
stretch marks, which represent a psychological burden for
many people. Despite the different therapeutic approaches
that are currently available, treating stretch marks
remains a challenge. Numerous methods have been put
forward, but results have been uneven [39]. Our prospec-
tive pilot study appears to show a positive effect after six
treatment sessions using the Er:YAG RecoSMA laser with
a wavelength of 2,940 nm. The advantage of this technol-
ogy is that the laser induces minimal ablative and thermal
effects, since the beam penetrates only 50 μm into the
thickness of the epidermis.

The results of our study pointed to improvement in
stretch marks for all patients: improvement of both texture
and color, with a significant increase in dermal thickness
as well as substantially increased skin elasticity. Measure-
ments of viscoelasticity showed that SD scars were
significantly less firm, less elastic, and less deformable
than normal skin [40].

Treatment with the multi-fractional RecoSMA laser
thus brought about significant improvement of skin
elasticity and firmness compared to the results of the
various cutometric parameters analyzed prior to treat-
ment of stretch marks. A larger patient cohort and a
control group would provide validation of the promising
results of our study.

Several nonablative wavelengths including the 1410,
1540, 1450, and 1565 nm lasers have been trialed in the
treatment of SD [41–43]. However, results have varied
significantly, ranging from moderate improvement to no
improvement, and side effects, such as significant ery-
theima and PIH have been reported with these modalities,
especially in patients of darker skin types [30,43].

In our patient population, five skin phototypes were
represented: 10% of patients had phototype III; 10% phototype VI; 25% phototype IV; 30% phototype I; and
25% phototype II. The RecoSMA laser thus demonstrated
its efficacy for both clear and dark phototypes, without
causing hyperpigmentation adverse effects.

Few studies have assessed the efficacy of the 2,940 nm
Er:YAG laser for the treatment of stretch marks. A study
by Gungor et al. compared the efficacy of a 1,064-nm
long-pulse laser and the 2,940-nm Er:YAG variable-pulse laser in 20 patients affected by mature and immature stretch marks. Patients received three treatment sessions each month. The clinical results, based on photographic comparisons, revealed moderate improvement in the appearance of stretch marks among patients with immature stretch marks, but patients with mature stretch marks showed no improvement. Histological results
indicating a slight increase in elastic fibers were reported [44]. These findings suggest that three treatment sessions are probably not sufficient to improve the appearance of stretch marks, particularly mature ones that are difficult to treat.

Two other studies have reported positive effects using the 2,940-nm Er:YAG laser. Gauglitz et al. conducted a study on two cases of axial stretch marks, showing that the 2,940-nm Er:YAG laser improved the texture and color in the two cases of mature and immature stretch marks after three and five treatment sessions [45].

The second study, published recently, assessed the efficacy of using the 2,940-nm Er:YAG laser combined with light-emitting diode-red light (LED-RL) treatment and an application of recombinant fibroblast growth factor (FGF) among 30 patients for the treatment of stretch marks located on different parts of the body. Patients received six treatment sessions at 4-week intervals, then

---

![Fig. 4. Ultrasound dermis thickness assessment. Statistical analysis highlighted a significant increase in dermis thickness at the end of the study (6 months). Relative changes in dermis thickness values during the study (mean ± standard deviation).](image)

![Fig. 5. Photographs Striae distensae before (left) and 6 months after treatment (six sessions total) (right). An improvement in texture, depression, and color of SD are noted.](image)
FGF applications for 1 week, followed by three LED-RL sessions. This approach resulted in improvement of stretch mark among all patients. Histological results showed an increase in epidermal and dermal thickness, as well as elastin density [46].

These findings agree with the results of our study, which showed that a significant improvement in stretch marks is observed after six laser sessions without adverse events and by reducing time to recovery. Therefore, the Er:YAG laser combined with the SMA technology have many advantages over conventional lasers including less risk of side effects, less discomfort, less recovery time, and no anesthesia is necessary.

Most of the patients (85%) noticed improvement in their stretch marks and expressed satisfaction with the treatment and only 15% noticed moderate and slight improvement. For this last group, we notified that the stage of SD was IIIb or IV and the maturity of stretch marks was between 20 and 32 years. Thus, we believe that it would be necessary to consider the stage and the maturity of SD to treat efficiently the stretch marks by increasing for example the number of treatment sessions or decrease the interval of treatment. Unfortunately, the smaller size of the sample did not allow us to perform a multivariate analysis to determine if there is a correlation between the treatment effect and the factors including: maturity of SD, the stage and the location of SD. Further larger and randomized studies might be needed to establish the optimal number of sessions and treatment interval to enhance treatment efficacy.

Otherwise, the histological analysis of stretch marks before and after treatment would have been useful; however, biopsies are too invasive, particularly in the field of aesthetic medicine. Confocal laser microscopy [46,47] has become the instrument of choice to perform optical biopsies but the challenge with this technique is its cost and steep learning curve.

CONCLUSION

Our prospective pilot study appears to show the efficacy of the RecoSMA laser combined with good tolerance for the treatment of various types of stretch marks in patients with different skin phototypes, with significant improvement of skin texture and quality assessed using objective, non-invasive tools. A randomized controlled study is necessary to validate these results.

ACKNOWLEDGMENT

Mounia SidAhmed-Mezi received a grant from Lineline to follow her research.

References

30. Alster TS, Lupton JR. Prevention and treatment of side effects
28. Guertler A, Reinholz M, Steckmeier S, Gauglitz GG. Evalu-
27. Stotland M, Chapas AM, Brightman L, et al. The safety and
22. Alexiades-Armenakas MR, Bernstein LJ, Friedman PM,
20. Hague A, Bayat A. Therapeutic targets in the management of
18. Park KY, Kim HK, Kim SE, Kim BJ, Kim MN. Treatment of
17. Al-Dhalimi MA, Abou Nasyria AA. A comparative study of the
16. Hernandez-Perez E, Colombo-Charrrier E, Valencia-Ilieti E.
15. Manuskiatti W, Bonhoutweeyuwat E, Varothai S. Treatment of
14. Abdel-Latif AM, Albendary AS. Treatment of striae distensae
12. Alexiades-Armenakas MR, Bernstein LJ, Friedman PM,
11. Adatto MA, Deprez P. Striae treated by a novel combination
10. Hague A, Bayat A. Therapeutic targets in the management of
9. Trelles MA, Khomchenko V, Alcolea JM, Martinez-Carpio PA.
8. Likert R. A technique for the measurement of attitudes. Arch
6. Stotland M, Chapas AM, Brightman L, et al. The safety and
5. Emelko M, Nouri K. Laser and light treatments for striae distensae: A
4. Tay YK, Kwok C, Tan E. Non-ablative 1,450-nm diode laser
2. Gauglitz GG, Reinhólz M, Kaudewitz P, et al. Treatment of
1. Alster TS, Lupton JR. Prevention and treatment of side effects

Er:YAG LASER WITH SMA MODULE FOR STRIAE DISTENSAE

9

11. Adatto MA, Deprez P. Striae treated by a novel combination
treatment—Sand abrasion and a patent mixture containing
15% trichloracetic acid followed by 6-24 hrs of a patent cream
12. Deprez P. Easy peel for the treatment of stretch marks. Int J
sion: A molecular analysis following a single treatment. J Am
14. Abdel-Latif AM, Albendary AS. Treatment of striae distensae
with microdermabrasion: A clinical and molecular study.
15. Manuskiatti W, Bonhoutweeyuwat E, Varothai S. Treatment of
striae distensae with a TriPollar radiofrequency device: A
16. Hernandez-Perez E, Colombo-Charrrier E, Valencia-Ilieti E.
Intense pulsed light in the treatment of striae distensae.
17. Al-Dhalimi MA, Abou Nasyria AA. A comparative study of the
effectiveness of intense pulsed light wavelengths (650 nm vs
590 nm) in the treatment of striae distensae. J Cosmet Laser
18. Park KY, Kim HK, Kim SE, Kim BJ, Kim MN. Treatment of
striae distensae using needling therapy: A pilot study.
Percutaneous collagen induction therapy: An alternative
treatment for scars, wrinkles, and skin laxity. Plast Reconstr
20. Hague A, Bayat A. Therapeutic targets in the management of
striae distensae: A systematic review. J Am Acad Dermatol
21. Jimenez GP, Flores F, Berman B, Gunja-Smith Z. Treatment of
striae rubra and striae alba with the 585-nm pulsed-dye
22. Alexiades-Armenakas MR, Bernstein LJ, Friedman PM,
Geronemus RG. The safety and efficacy of the 308-nm excimer
laser for pigment correction of hypopigmented scars and
23. Goldman A, Rossato F, Prati C. Stretch marks: Treatment
using the 1064-nm Nd:YAG laser. Dermatol Surg 2008;34:
686–692.
follow-up results of copper bromide laser treatment of striae.
25. de Angelis F, Kolesnikova L, Renato F, Licuorgi F. Fractional
nonablative 1540-nm laser treatment of striae distensae in
Fitzpatrick skin types II to IV: Clinical and histological
1540-nm and a 1410-nm nonablative fractionated laser for the
27. Stotland M, Chapas AM, Brightman L, et al. The safety and
efficacy of fractional photothermolysis for the correction of
28. Guertler A, Reinholz M, Steckmeier S, Gauglitz GG. Evalua-
tion of a non-ablative, fractional 1565 nm laser for the
improvement of striae distensae albae. J Eur Acad Dermatol
using an ablative 10600-nm carbon dioxide fractional laser: A
retrospective review of 27 participants. Dermatol Surg
30. Alster TS, Lupton JR. Prevention and treatment of side effects
and complications of cutaneous laser resurfacing. Plast